Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice

Eun Gyoung Hong, Brian W. Kim, Dae Young Jung, Jong Hun Kim, Tim Yu, Wagner Seixas Da Silva, Randall H. Friedline, Suzy D. Bianco, Stephen P. Seslar, Hiroko Wakimoto, Charles I. Berul, Kerry S. Russell, Ki Won Lee, P. Reed Larsen, Antonio C. Bianco, Jason K. Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Altered glucose metabolism in the heart is an important characteristic of cardiovascular and metabolic disease. Because thyroid hormones have major effects on peripheral metabolism, we examined the metabolic effects of heart-selective increase in T3 using transgenic mice expressing human type 2 iodothyronine deiodinase (D2) under the control of the α-myosin heavy chain promoter (MHC-D2). Hyperinsulinemic-euglycemic clamps showed normal whole-body glucose disposal but increased hepatic insulin action in MHC-D2 mice as compared to wild-type (WT) littermates. Insulin-stimulated glucose uptake in heart was not altered, but basal myocardial glucose metabolism was increased by more than two-fold in MHC-D2 mice. Myocardial lipid levels were also elevated in MHC-D2 mice, suggesting an overall up-regulation of cardiac metabolism in these mice. The effects of doxorubicin (DOX) treatment on cardiac function and structure were examined using M-mode echocardiography. DOX treatment caused a significant reduction in ventricular fractional shortening and resulted in more than 50% death in WT mice. In contrast, MHC-D2 mice showed increased survival rate after DOX treatment, and this was associated with a six-fold increase in myocardial glucose metabolism and improved cardiac function. Myocardial activity and expression of AMPK, GLUT1, and Akt were also elevated in MHC-D2 and WT mice following DOX treatment. Thus, our findings indicate an important role of thyroid hormone in cardiac metabolism and further suggest a protective role of glucose utilization in DOX-mediated cardiac dysfunction.

Original languageEnglish
Pages (from-to)3937-3946
Number of pages10
JournalEndocrinology
Volume154
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Iodide Peroxidase
Doxorubicin
Glucose
Thyroid Hormones
Insulin
AMP-Activated Protein Kinases
Glucose Clamp Technique
Myosin Heavy Chains
Metabolic Diseases
Transgenic Mice
Echocardiography
Cardiovascular Diseases
Up-Regulation
Lipids
Liver

ASJC Scopus subject areas

  • Endocrinology

Cite this

Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice. / Hong, Eun Gyoung; Kim, Brian W.; Jung, Dae Young; Kim, Jong Hun; Yu, Tim; Da Silva, Wagner Seixas; Friedline, Randall H.; Bianco, Suzy D.; Seslar, Stephen P.; Wakimoto, Hiroko; Berul, Charles I.; Russell, Kerry S.; Lee, Ki Won; Larsen, P. Reed; Bianco, Antonio C.; Kim, Jason K.

In: Endocrinology, Vol. 154, No. 10, 01.10.2013, p. 3937-3946.

Research output: Contribution to journalArticle

Hong, EG, Kim, BW, Jung, DY, Kim, JH, Yu, T, Da Silva, WS, Friedline, RH, Bianco, SD, Seslar, SP, Wakimoto, H, Berul, CI, Russell, KS, Lee, KW, Larsen, PR, Bianco, AC & Kim, JK 2013, 'Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice', Endocrinology, vol. 154, no. 10, pp. 3937-3946. https://doi.org/10.1210/en.2012-2261
Hong, Eun Gyoung ; Kim, Brian W. ; Jung, Dae Young ; Kim, Jong Hun ; Yu, Tim ; Da Silva, Wagner Seixas ; Friedline, Randall H. ; Bianco, Suzy D. ; Seslar, Stephen P. ; Wakimoto, Hiroko ; Berul, Charles I. ; Russell, Kerry S. ; Lee, Ki Won ; Larsen, P. Reed ; Bianco, Antonio C. ; Kim, Jason K. / Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice. In: Endocrinology. 2013 ; Vol. 154, No. 10. pp. 3937-3946.
@article{9a0375fa918d4136861dc96adaa75e96,
title = "Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice",
abstract = "Altered glucose metabolism in the heart is an important characteristic of cardiovascular and metabolic disease. Because thyroid hormones have major effects on peripheral metabolism, we examined the metabolic effects of heart-selective increase in T3 using transgenic mice expressing human type 2 iodothyronine deiodinase (D2) under the control of the α-myosin heavy chain promoter (MHC-D2). Hyperinsulinemic-euglycemic clamps showed normal whole-body glucose disposal but increased hepatic insulin action in MHC-D2 mice as compared to wild-type (WT) littermates. Insulin-stimulated glucose uptake in heart was not altered, but basal myocardial glucose metabolism was increased by more than two-fold in MHC-D2 mice. Myocardial lipid levels were also elevated in MHC-D2 mice, suggesting an overall up-regulation of cardiac metabolism in these mice. The effects of doxorubicin (DOX) treatment on cardiac function and structure were examined using M-mode echocardiography. DOX treatment caused a significant reduction in ventricular fractional shortening and resulted in more than 50{\%} death in WT mice. In contrast, MHC-D2 mice showed increased survival rate after DOX treatment, and this was associated with a six-fold increase in myocardial glucose metabolism and improved cardiac function. Myocardial activity and expression of AMPK, GLUT1, and Akt were also elevated in MHC-D2 and WT mice following DOX treatment. Thus, our findings indicate an important role of thyroid hormone in cardiac metabolism and further suggest a protective role of glucose utilization in DOX-mediated cardiac dysfunction.",
author = "Hong, {Eun Gyoung} and Kim, {Brian W.} and Jung, {Dae Young} and Kim, {Jong Hun} and Tim Yu and {Da Silva}, {Wagner Seixas} and Friedline, {Randall H.} and Bianco, {Suzy D.} and Seslar, {Stephen P.} and Hiroko Wakimoto and Berul, {Charles I.} and Russell, {Kerry S.} and Lee, {Ki Won} and Larsen, {P. Reed} and Bianco, {Antonio C.} and Kim, {Jason K.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1210/en.2012-2261",
language = "English",
volume = "154",
pages = "3937--3946",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice

AU - Hong, Eun Gyoung

AU - Kim, Brian W.

AU - Jung, Dae Young

AU - Kim, Jong Hun

AU - Yu, Tim

AU - Da Silva, Wagner Seixas

AU - Friedline, Randall H.

AU - Bianco, Suzy D.

AU - Seslar, Stephen P.

AU - Wakimoto, Hiroko

AU - Berul, Charles I.

AU - Russell, Kerry S.

AU - Lee, Ki Won

AU - Larsen, P. Reed

AU - Bianco, Antonio C.

AU - Kim, Jason K.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Altered glucose metabolism in the heart is an important characteristic of cardiovascular and metabolic disease. Because thyroid hormones have major effects on peripheral metabolism, we examined the metabolic effects of heart-selective increase in T3 using transgenic mice expressing human type 2 iodothyronine deiodinase (D2) under the control of the α-myosin heavy chain promoter (MHC-D2). Hyperinsulinemic-euglycemic clamps showed normal whole-body glucose disposal but increased hepatic insulin action in MHC-D2 mice as compared to wild-type (WT) littermates. Insulin-stimulated glucose uptake in heart was not altered, but basal myocardial glucose metabolism was increased by more than two-fold in MHC-D2 mice. Myocardial lipid levels were also elevated in MHC-D2 mice, suggesting an overall up-regulation of cardiac metabolism in these mice. The effects of doxorubicin (DOX) treatment on cardiac function and structure were examined using M-mode echocardiography. DOX treatment caused a significant reduction in ventricular fractional shortening and resulted in more than 50% death in WT mice. In contrast, MHC-D2 mice showed increased survival rate after DOX treatment, and this was associated with a six-fold increase in myocardial glucose metabolism and improved cardiac function. Myocardial activity and expression of AMPK, GLUT1, and Akt were also elevated in MHC-D2 and WT mice following DOX treatment. Thus, our findings indicate an important role of thyroid hormone in cardiac metabolism and further suggest a protective role of glucose utilization in DOX-mediated cardiac dysfunction.

AB - Altered glucose metabolism in the heart is an important characteristic of cardiovascular and metabolic disease. Because thyroid hormones have major effects on peripheral metabolism, we examined the metabolic effects of heart-selective increase in T3 using transgenic mice expressing human type 2 iodothyronine deiodinase (D2) under the control of the α-myosin heavy chain promoter (MHC-D2). Hyperinsulinemic-euglycemic clamps showed normal whole-body glucose disposal but increased hepatic insulin action in MHC-D2 mice as compared to wild-type (WT) littermates. Insulin-stimulated glucose uptake in heart was not altered, but basal myocardial glucose metabolism was increased by more than two-fold in MHC-D2 mice. Myocardial lipid levels were also elevated in MHC-D2 mice, suggesting an overall up-regulation of cardiac metabolism in these mice. The effects of doxorubicin (DOX) treatment on cardiac function and structure were examined using M-mode echocardiography. DOX treatment caused a significant reduction in ventricular fractional shortening and resulted in more than 50% death in WT mice. In contrast, MHC-D2 mice showed increased survival rate after DOX treatment, and this was associated with a six-fold increase in myocardial glucose metabolism and improved cardiac function. Myocardial activity and expression of AMPK, GLUT1, and Akt were also elevated in MHC-D2 and WT mice following DOX treatment. Thus, our findings indicate an important role of thyroid hormone in cardiac metabolism and further suggest a protective role of glucose utilization in DOX-mediated cardiac dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=84884679972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884679972&partnerID=8YFLogxK

U2 - 10.1210/en.2012-2261

DO - 10.1210/en.2012-2261

M3 - Article

C2 - 23861374

AN - SCOPUS:84884679972

VL - 154

SP - 3937

EP - 3946

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 10

ER -